FLUORESCENT MARKERS FOR BREAST CANCER SURGERY

用于乳腺癌手术的荧光标记物

• 批准号: 6189733
• 负责人: CHARLES Buell GRISSOM
• 金额: $ 11.21万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-07-14 至 2002-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6189733
• 关键词: Animalia; biopsy; breast neoplasm /cancer diagnosis; breast neoplasms; chemical conjugate; clinical research; cobalamin; drug design /synthesis /production; drug screening /evaluation; fluoresceins; fluorescence microscopy; fluorescent dye /probe; human subject; lymph node neoplasm; metastasis; neoplasm /cancer surgery; surface plasmon resonance

DESCRIPTION: (Applicant's Description) The purpose of this project is to synthesize six fluorescent cobalamin derivatives and select the optimal compound for use as an improved tumor marker in the sentinel lymph node biopsy procedure for breast cancer . Our work to date has shown that all cancer and leukemia cell lines tested have an unusually high requirement for cobalamin (Vitamin B12). A fluorescent derivative of cobalamin should be a good visual marker that is specific for cancer cells and thereby aid in the visual identification of metastatic disease in lymph ducts and nodes. A fluorescent cobalamin conjugate may also improve the definition of tumor micro margins and aid in the surgical excision of cancerous tissue while sparing healthy tissue. As an intraoperative marker for metastatic breast disease, it may decrease the false-negative rate of the sentinel node biopsy procedure as it is currently practiced and provide a better quality of life for patients through the preservation of healthy breast tissue and healthy axial lymph nodes. This proposal will fund the initial evaluation of a fluorescein-cobalamin derivative we now have in hand, and fund the synthesis and evaluation of several second-generation fluorescent cobalamin conjugates that should be brighter and more photostable than our existing compound. Fluorescent cobalamin conjugates will be tested in primary human tumors that are removed from patients undergoing breast cancer operations.

描述：(申请人描述) 本项目的目的是合成六种荧光钴胺。 并选择最佳化合物作为改进的肿瘤使用 乳腺癌前哨淋巴结活检术的标志物。我们的 到目前为止的研究表明，所有测试的癌症和白血病细胞系都有一个 对钴素(维生素B12)的要求异常高。一种荧光灯 钴胺衍生物应是一种良好的视觉标记物 癌细胞，从而有助于转移的目视识别 淋巴管和结节的疾病。荧光钴胺结合物还可以 提高肿瘤微边界的清晰度，辅助手术 切除癌组织，同时保留健康组织。作为一种 转移性乳腺疾病的术中标志物，它可能会降低 前哨淋巴结活检术目前的假阴性率 为患者提供更好的生活质量 保存健康的乳房组织和健康的中轴淋巴结。这 提案将为荧光素-钴胺的初步评估提供资金 我们现在手中有衍生品，并为合成和评估 几种第二代荧光钴胺结合物，应该是 比我们现有的化合物更亮，更耐光。荧光 钴胺结合物将在切除的原发人类肿瘤中进行测试 来自接受乳腺癌手术的患者。